D. E. Shaw & Co. Inc. Sells 105,619 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

D. E. Shaw & Co. Inc. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 56.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,578 shares of the company's stock after selling 105,619 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.13% of Kymera Therapeutics worth $3,322,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Northern Trust Corp grew its position in shares of Kymera Therapeutics by 14.0% in the 4th quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after acquiring an additional 53,658 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after purchasing an additional 20,346 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Kymera Therapeutics by 174.2% during the fourth quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock worth $801,000 after purchasing an additional 12,643 shares during the period. Wells Fargo & Company MN increased its position in Kymera Therapeutics by 51.8% during the fourth quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock worth $883,000 after buying an additional 7,487 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its stake in Kymera Therapeutics by 35.8% in the fourth quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company's stock valued at $462,000 after buying an additional 3,026 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. UBS Group dropped their price target on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Guggenheim reissued a "buy" rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research report on Monday, May 12th. Stifel Nicolaus initiated coverage on shares of Kymera Therapeutics in a research note on Tuesday. They set a "buy" rating and a $55.00 target price for the company. Stephens reiterated an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, HC Wainwright raised their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $55.25.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR traded down $1.31 during mid-day trading on Wednesday, reaching $30.13. The company had a trading volume of 572,983 shares, compared to its average volume of 562,849. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27. The business's 50-day simple moving average is $29.23 and its 200 day simple moving average is $36.76. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -12.88 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million during the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business's revenue for the quarter was up 114.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.69) EPS. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This trade represents a 3.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This represents a 2.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,659 shares of company stock worth $324,567 over the last three months. Corporate insiders own 16.01% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.